>
$93.18 -0.4 -0.4%
Last Trade - 6:55pm
Market Cap | £15.05bn |
Enterprise Value | £14.28bn |
Revenue | £1.58bn |
Position in Universe | 569th / 6852 |
Industry | Market | |
---|---|---|
|
|
|
|
|
|
|
|
Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
---|---|---|---|---|---|---|---|---|---|---|
757 | 981.1 | 1,056 | 1,208 | 1,300 | 2,200 | 2,800 | 3,482 | +23.8% | ||
-31.0 | +67.7 | +39.2 | ||||||||
x
|
||||||||||
Profitability | ||||||||||
%
|
||||||||||
%
|
||||||||||
%
|
||||||||||
Cashflow | ||||||||||
Dividends | ||||||||||
Balance Sheet | ||||||||||
m
|
||||||||||
m
|
||||||||||
m
|
||||||||||
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing % | |||
Net Gearing % | |||
Cash / Assets % |
Liquidity (ttm) | ||
---|---|---|
Curr. Ratio | ||
Quick Ratio | ||
Interest Cov. |
Efficiency (ttm) | ||
---|---|---|
Asset Turnover | ||
Recs Turnover | ||
Stock Turnover |
Latest interim period vs. prior period | Industry | Market |
---|---|---|
|
|
|
|
|
3yr Compound Annual Growth Rate | Industry | Market |
---|---|---|
|
|
|
|
|
|
|
|
Horizon Therapeutics plc, formerly Horizon Pharma plc, is a rare disease biopharmaceutical company. The Company is focused on researching, developing and commercializing medicines that address needs for people impacted by rare and rheumatic diseases. The Company markets approximately 10 medicines, of which 6 are for rare and rheumatic diseases. The Company's marketed medicines are ACTIMMUNE (interferon gamma-1b), BUPHENYL (sodium phenylbutyrate) Tablets and Powder, DUEXIS (ibuprofen/famotidine), KRYSTEXXA (pegloticase), PENNSAID (diclofenac sodium topical solution) 2% weight per weight (w/w), or PENNSAID 2%, PROCYSBI (cysteamine bitartrate) delayed-release capsules, QUINSAIR (aerosolized form of levofloxacin), RAVICTI (glycerol phenylbutyrate) Oral Liquid, RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium).
Last Annual | December 31st, 2020 |
Last Interim | December 31st, 2020 |
Incorporated | December 20, 2011 |
Public Since | August 11, 2010 |
No. of Shareholders: | 9 |
No. of Employees: | 1,395 |
Sector | Healthcare |
Industry | Pharmaceuticals |
Index | Nasdaq Composite , |
Exchange | NASDAQ Global Select Market |
Shares in Issue | 224,074,399 |
Free Float | (0.0%) |
Eligible for |
✓
ISAs
✓
SIPPs
|
Address | Connaught House,1St Floor 1 Burlington Road, DUBLIN, D04 C5Y6, Ireland |
Web | https://www.horizontherapeutics.com/ |
Phone | +353 1 7722100 |
Contact | Tina Ventura (Senior Vice President, Investor Relations) |
Auditors | PricewaterhouseCoopers LLP |
As of 6:55pm, shares in Horizon Therapeutics are trading at $93.18, giving the company a market capitalisation of £15.05bn. This share price information is delayed by 15 minutes.
Shares in Horizon Therapeutics are currently trading at $93.18 and the price has moved by 0.187k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Horizon Therapeutics price has moved by 94.33% over the past year.
Of the analysts with advisory recommendations for Horizon Therapeutics, there are there are currently 6 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Horizon Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Horizon Therapeutics is scheduled to issue upcoming financial results on the following dates:
Horizon Therapeutics does not currently pay a dividend.
Horizon Therapeutics does not currently pay a dividend.
Horizon Therapeutics does not currently pay a dividend.
To buy shares in Horizon Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Horizon Therapeutics are currently trading at $93.18, giving the company a market capitalisation of £15.05bn.
Here are the trading details for Horizon Therapeutics:
Based on an overall assessment of its quality, value and momentum, Horizon Therapeutics is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Horizon Therapeutics are currently priced at $93.18. At that level they are trading at 21.86% discount to the analyst consensus target price of 0.00.
Analysts covering Horizon Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of 3.628 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Horizon Therapeutics. Over the past six months, the relative strength of its shares against the market has been -0.64%. At the current price of $93.18, shares in Horizon Therapeutics are trading at 21.36% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Horizon Therapeutics PE ratio based on its reported earnings over the past 12 months is 43.24. The shares are currently trading at $93.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Horizon Therapeutics's management team is headed by:
Here are the top five shareholders of Horizon Therapeutics based on the size of their shareholding: